Dicerna Pharmaceuticals

Dicerna

Pipeline

Pipeline

RNAi therapies to target the cause of disease

We are developing a pipeline of RNAi therapies that aim to restore health by addressing the underlying cause of disease. We strive to deliver life-changing therapies as efficiently as possible to meet the urgent needs of individuals living with rare and common diseases. 

Key core programs

Nedosiran is Dicerna’s lead investigational RNAi therapy in development for the treatment of primary hyperoxaluria (PH).

RG6346 is an investigational RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic hepatitis B virus (HBV) infection. 

AAT

Belcesiran (DCR-A1AT) is an investigational RNAi therapeutic candidate in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease (AATLD).

DCR-AUD is an investigational RNAi therapy developed with Dicerna’s GalXC technology for the treatment of alcohol use disorder. 

Our mission

We interfere with disease

We use RNA interference, or RNAi, to create medicines that silence the genes that cause or contribute to disease. Our goal is to provide life-changing therapies to people living with rare and common diseases.